Adipocyte insulin resistance can be caused by proximal insulin signaling defects but also from postreceptor mechanisms, which in large are poorly characterized. Adipocytes exposed for 18 h to the HIV protease inhibitor nelfinavir manifest insulin resistance characterized by normal insulinstimulated tyrosine phosphorylation of the insulin receptor and insulin receptor substrate proteins, preserved in vitro phosphatidylinositol 3-kinase (PI 3-kinase) assay activity but impaired activation of PKB/Akt and stimulation of glucose uptake. Here we aimed to assess whether impaired PKB/Akt activation is indeed rate limiting for insulin signaling propagation in response to nelfinavir and the mechanism for defective PKB/Akt activation. Nelfinavir treatment of 3T3-L1 adipocytes impaired the insulin-stimulated translocation and membrane fusion of myc-glucose transporter (GLUT)-4-green fluorescent protein (GFP) reporter. Phosphorylation of PKB/Akt substrates including glycogen synthase kinase-3 and AS160 decreased in response to nelfinavir, and this remained true, even in cells with forced generation of phosphatidylinositol-3,4,5-trisphohphate (PIP 3 ) by a membranetargeted active PI 3-kinase, confirming that impaired PKB/Akt activation was rate limiting for insulin signal propagation. Cells expressing a GFP-tagged pleckstrin homology domain of general receptors for phosphoinositides 1, which binds PIP 3 , revealed intact PIP 3 -mediated plasma membrane translocation of this reporter in nelfinavir-treated cells. However, expression of a membrane-targeted catalytic subunit of PI 3-kinase failed to induce myc-GLUT4-GFP translocation in the absence of insulin, as it did in control cells. Conversely, a membrane-targeted and constitutively active PKB/Akt mutant was normally phosphorylated on S473 and T308, confirming intact PKB/Akt kinases activity, and induced myc-GLUT4-GFP translocation. Collectively, nelfinavir uncovers a postreceptor mechanism for insulin resistance, caused by interference with the sensing of PIP 3 by PKB/Akt, leading to impaired GLUT4 translocation and membrane fusion. 
D
espite substantial progress in our understanding of insulin signaling, the molecular basis for insulin resistance in adipocytes, a condition present in various common conditions like obesity and diabetes, still remains enigmatic. Impairment in early insulin signaling events, like the tyrosine phosphorylation of the insulin receptor and of insulin receptor substrates (IRS), has been documented both in vivo and in various experimental models (1) (2) (3) (4) . Yet it remains unclear whether defective early insulin signaling constitutes the rate-limiting step for the downstream propagation of the insulin-initiated signal. Furthermore, various inducers of insulin resistance, including ceramide (5, 6), oxidative stress (7) , and GH (8) , do so without affecting insulin re-ceptor activation, suggesting that signaling step(s) more distal to the insulin receptor and its immediate substrates are the functional break points in insulin action. One such candidate is the propagation of the signal from phosphatidylinositol 3-kinase (PI 3-kinase) to PKB/Akt, a process consisting of several events, including the generation of the major PI 3-kinase product phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ) , the recruitment of PKB/Akt and its upstream kinase phosphoinosotide-dependent kinase (PDK)-1 to the plasma membrane through their pleckstrin homology (PH) domains, and a dual phosphorylation of PKB/ Akt on Thr308 by PDK1 and Ser473 by the mammalian target of rapamycin (mTOR)-signaling complex 2 (9 -12) . Indeed, impaired insulin-stimulated PKB/Akt phosphorylation has been noted in insulin-resistant adipocytes, whether or not upstream signaling defects are present (1, 13) . Given that activation of PKB/Akt is likely a required step for most of insulin's key actions (9) , it is possible that insulin-induced PKB/Akt activation constitutes a critical integration nexus in the insulin signaling cascade. Several molecular mechanisms to explain impaired PKB/ Akt activation despite normal activation of PI 3-kinase (as assessed in an in vitro kinase assay) have been proposed. They include up-regulated activity of protein phosphatase 2A (PP2A; a major PKB/Akt phosphatase) (14) , defective subcellular localization of PI 3-kinase and/or PKB/Akt (13, 15) , impaired in vivo PIP 3 generation despite normal in vitro kinase activity (16) , phosphorylation of PKB/Akt on its PH domain by protein kinase C (PKC)- (17, 18) , and complex formation between PKB/Akt and Drosophila Tribbles homologue protein 3 (TRB3) (19) .
Despite all of the above, several studies questioned the possibility that PKB/Akt is indeed the reason for impaired insulin action in insulin resistance conditions (20) . Even when its activity is diminished, a large fractional inhibition of PKB/Akt activity (Ͼ80%) was required to attenuate glucose transporter (GLUT)-4 translocation in muscle cells (21) . Because most inducers of insulin resistance impair PKB/Akt activation to a lesser degree, it remains possible that under some circumstances other signaling steps constitute the rate-limiting step(s) in insulin action (22) .
Nelfinavir is an HIV protease inhibitor used as part of the antiretroviral chemotherapeutic cocktail. Insulin resistance and accompanying diabetes and accelerated atherosclerosis have been reported as serious side effects of this drug and other members of this class of protease inhibitors (23) . Nelfinavir-induced insulin resistance has been successfully recapitulated in cellular adipocyte models (24 -27) . These studies demonstrated that although HIV protease inhibitors acutely inhibit GLUT4 function without affecting insulin signaling (26, 28 -30) , when adipocytes are exposed to nelfinavir for 18 h, an insulin signaling defect is induced characterized by normal proximal signaling events, intact insulin-stimulated activation of PI 3-kinase (as measured by an in vitro kinase assay), but with impaired phosphorylation on both Ser and Thr residues of PKB/Akt and a resulting defective activation of the enzyme. A previous study ruled out increased PP2A activity or elevated expression of the PIP 3 phosphatases [phosphatase and tensin homolog deleted from chromosome 10 (PTEN) and SH 2 -containing inositol 5Ј-phosphate 2 (SHIP2) as underling mechanism (25) , leaving the mechanism for defective PI 3-kinase to PKB/Akt signal transmission unresolved. Here we undertook to investigate the molecular mechanisms for nelfinavir-induced impairment in PKB/Akt activation, and to establish that defective PKB/Akt sensing of insulin-stimulated generation of PIP 3 underlies the impaired ability of insulin to recruit GLUT4 to the plasma membrane.
Materials and Methods

Materials and reagents
Tissue culture medium, serum, and antibiotic solutions were obtained from Biological Industries (Beit-Haeemek, Israel). Recombinant human insulin was from Novo Nordisk (Bagsvaerd, Denmark). Anti-PKB/Akt, anti-pSer473 Akt/PKB, anti-pThr308 Akt/PKB, anti-pAkt substrate (PAS), anti-AS160, anti-pSer21/9 glycogen synthase kinase (GSK)-3␣/␤ were purchased from Cell Signaling (Beverly, MA.). Antic-Myc was from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-␤-actin was from Sigma (St. Louis, MO). Alexa Fluor 555 antibody was from Molecular Probes (Eugene, OR). Nelfinavir was supplied by Roche Pharmaceuticals (Tel Aviv, Israel). The myc-GLUT4-enhanced green fluorescent protein and green fluorescent protein (GFP)-general receptor for phosphoinositides (GRP)-PH constructs have been described previously (16, 31) . The myrAKT plasmid was a kind gift from Dr. Michael Quon (National Institutes of Health, Bethesda, MD). The p110-CAAX construct was described previously (32) .
Cell culture and treatment
3T3-L1 preadipocytes (American Type Culture Collection, Manassas, VA) were cultured and induced to differentiate as we previously reported (7, 13) . Cells were used 6 -10 d after differentiation induction (for electroporation cells were maintained in medium supplemented with insulin until d 6 after differentiation induction). Nelfinavir treatment was performed by adding the drug to serum-free DMEM supplemented with 0.5% RIA-grade BSA, to a final concentration of 30 mol/liter, for 18 h. The final nelfinavir medium concentration was achieved by the appropriate dilution of a 100 mmol/liter stock solution prepared in 100% ethanol.
Electroporation
Cells from 100-mm plates of 3T3-L1 adipocytes 6 d after differentiation were collected after gentle trypsinization and three washes (by centrifugation) in PBS into two to three electroporation cuvettes, into which 50 g of DNA [GRP1-PH-GFP and GFP GLUT4 myc )] or 150 g p110-CAAX and myr-Akt plasmids (for cotransfection experiments) were added. Cells were electroporated using a Gene Pulser II (Bio-Rad Laboratories, Hercules, CA) at 0.16 kV and 950 F. After electroporation, cells were plated on collagen IV-coated glass coverslips in 6-well plates and allowed to recover in DMEM supplemented with 10% serum for 4 h before treatment with nelfinavir.
GRP1(PH)-GFP redistribution
Transfected 3T3-L1 adipocytes were starved for 18 h and treated for 10 min with or without 100 nmol/liter insulin prepared in serum-free medium. Cells were washed in PBS and fixed with 4% paraformaldehyde (PFA) in PBS for 5 min at 4 C and an additional 25 min at room temperature. Excess PFA was then quenched for 10 min with 100 mmol/liter glycine in PBS, and coverslips were mounted onto glass slides. The cells were imaged using a LSM 510 confocal microscope (Zeiss, Jena, Germany).
buffer containing 5% goat serum at 4 C. Cells were incubated with primary anti-myc antibody at 1:100 dilution in blocking buffer, and the antibody was detected using antimouse IgG conjugated with Alexa 555 in 1:750 dilution. The cells were then fixed with 4% PFA in PBS for 5 min at 4 C and an additional 25 min at room temperature. Paraformaldehyde was quenched for 10 min in 100 mmol/liter glycine in PBS. The cells were imaged using a Zeiss LSM 510 confocal microscope.
Quantitation of Myc-GLUT4-GFP translocation
Images of 20 -30 individual adipocyte cells (rounded morphology with visible lipid droplets) per experiment were analyzed for their GFP and myc staining morphology. Images were taken using the same acquisition and gain parameters throughout the experiment. The rim score of GFP (total Myc-GLUT4-GFP) or myc (GLUT4 molecules fused with the plasma membrane) was rated using the following scoring system: 0, no rim; 1, light-intensity and/or discontinuous rim staining; and 2, strong and continuous rim staining, similar to the approach used in (33) . The myc to GFP fluorescence ratio was done as reported elsewhere (34) . Rating was performed being blinded to the specific cell treatment.
Cell lysates and Western blots
Cells were rinsed three times with PBS and incubated in the absence or presence of 100 nmol/liter insulin for 7 min and then scraped into 0.25 ml/well of ice-cold lysis buffer [50 mmol/liter Tris-HCl (pH 7.5), 0.1% (vol/vol) Triton X-100, 1 mmol/liter EDTA, 1 mmol/liter EGTA, 50 mmol/liter NaF, 10 mmol/liter sodium-glycerophosphate, 5 mmol/liter sodium pyrophosphate, 1 mmol/liter sodium vanadate, 0.1% (vol/vol) 2-mercaptoethanol, and inhibitors (1:1000 dilution of protease inhibitor cocktail; Sigma)]. Lysate protein content was determined using the BioRad Bradford procedure. Proteins were resolved by SDS-PAGE and subjected to Western blot analyses, followed by quantification using image analysis software (ImageGauge version 4.0; Fuji, Tokyo, Japan). In each experiment the intensity of the band derived from control cells was assigned a value of 1 arbitrary unit, and the intensity of all treatment groups was expressed as fold of control.
Statistical analysis
Data are expressed as means Ϯ SE. Each treatment was compared with the control, and statistical significance between two groups was evaluated using the Student's t test. P Ͻ 0.05 was considered significant.
Results
Nelfinavir impairs insulin-stimulated translocation and fusion of GLUT4 with the plasma membrane and inhibits PKB/Akt activation
To dissect out the signaling defect responsible for impaired insulin-stimulated translocation of GLUT4 to the plasma membrane, we used a single-cell assay to assess GLUT4 translocation. 3T3-L1 adipocytes were electroporated with a plasmid encoding a myc-GLUT4-GFP dual-tagged transporter that serves as a single cell quantitative reporter of GLUT4 fusion with the plasma membrane. Because the myc epitope is inserted in the first exofacial loop of GLUT4, it is externalized upon fusion of vesicles containing myc-GLUT4-GFP with the plasma membrane (PM), making it available for labeling with a myc antibody in nonpermeabilized cells. In control cells in the absence of insulin, cells expressing myc-GLUT4-GFP were identified by their green fluorescence, which is mostly distributed in perinuclear regions (Fig. 1A, upper left panels) . Myc staining is low or undetectable, consistent with a low level of fused GLUT4 in the PM under basal conditions. In response to insulin GLUT4 vesicles translocated to the PM forming a GFP rim, and in addition, a rim of externalized myc became observable, consistent with insulin-induced GLUT4 vesicle fusion with the PM (Fig. 1A , upper right panels). Cells exposed for 18 h to nelfinavir showed decreased insulin-induced GLUT4 translocation (as assessed by GFP rims) and GLUT4 vesicle fusion (as assessed by myc rims). These observations using a single-cell assay were quantified as described in Materials and Methods, and the results are depicted in Fig. 1 , B and C. The single-cell assay is consistent with previously published observations, which demonstrated nelfinavirinduced impairment in insulin-stimulated GLUT4 translocation using both subcellular fractionation approach and the PM lawn assay (25, 27) .
We have previously shown, that nelfinavir-induced insulin resistance was associated with normal insulin receptor and IRS tyrosine phosphorylation as well as normal (or even exaggerated) PI 3-kinase activity in response to insulin stimulation (27) . Yet PKB/Akt phosphorylation on both Ser473 and Thr308 and its activity were impaired (25) . Because a marked inhibition of PKB/Akt activation was reported to be required to impair signal transmission downstream of PKB/Akt, we assessed whether signaling steps downstream of PKB/Akt were affected. For this we used the anti-PAS antibody. This antibody recognizes proteins phosphorylated on Ser/Thr residues within PKB/Akt's consensus sequence motif R/KxR/KxxR/KxS/T (35) . Two exposures of these blots are presented to enable the visualization of both highly and less abundant PKB/Akt substrates, without signal saturation ( Fig. 2A) . As can be seen, acute insulin stimulation increased the intensity of bands observable with PAS antibody, consistent with previous reports (35) . Nelfinavir treatment blunted insulin-stimulated phosphorylation of most of these bands, although to varying degrees (densitometry analysis revealed that nelfinavir treatment inhibited the mean net insulin stimulated increase in the intensity of the various bands by 33 to more than 90%). Consistent with the decrease in PKB/Akt Ser473 phosphorylation, nelfinavir impaired insulin-induced phosphorylation of GSK3 on Ser9 without significantly altering the total amount of either PKB/Akt or GSK3 (Fig. 2B) . Furthermore, nelfinavir attenuated insulin-stimulated phosphorylation of a 160-kDa Akt substrate, identified as AS160 [ Fig. 2C (35) ]. This PKB/Akt substrate has been implicated in downstream signal propagation from PKB/Akt to GLUT4 translocation and fusion (36 -38) . Collectively, these data demonstrate that nelfinavirinduced impairment in insulin-stimulated GLUT4 translocation and fusion with the PM is readily observable by a single-cell assay and provides evidence that it can be attributed to impaired insulin signaling downstream from PKB/Akt. 3 -mediated translocation to the plasma membrane, and a membrane-targeted active PI 3-kinase cannot bypass the defect in GLUT4 translocation induced by nelfinavir
Nelfinavir does not impair insulin-induced PIP
Because impaired in situ PIP 3 generation could be defective even when PI 3-kinase activity is intact as assessed by an in vitro kinase assay (16), we sought to functionally estimate insulinstimulated PIP 3 production in intact cells using a single-cell assay approach. For this, cells were electroporated in the presence of a plasmid encoding a fusion protein composed of GFP and the PH domain of GRP1. Because this PH domain has a rather selective affinity to PIP 3 binding (compared with other PIPs) (39), the translocation of GRP1(PH)-GFP from the cytosol to the cell periphery upon insulin stimulation is a reliable functional measure of insulin-induced PIP 3 generation in intact cells. Consistent with previous reports, this fusion protein strongly localizes with the cell nucleus, but this localization does not reflect PIP 3 binding (40) . Therefore, the extranuclear localization of GRP1(PH)-GFP is used for assessing PIP 3 production. In the absence of insulin stimulation, GRP1(PH)-GFP exhibited a diffuse cytosolic localization in both control and nelfinavir-treated cells (Fig. 3, left  panels) . In response to insulin, GRP1(PH)-GFP localized to the cell periphery. Remarkably, nelfinavir treatment did not appreciably affect insulin-induced GRP1(PH)-GFP relocalization (Fig.  3, right column) . Similar observations were obtained when GRP1(PH)-GFP was introduced to 3T3-L1 adipocytes by microinjection followed by live-cell microscopy (data not shown).
To determine whether forced PM generation of PIP 3 could overcome nelfinavir-induced defect in insulin signaling, we used a p110 catalytic subunit of PI 3-kinase targeted to the PM by virtue of a CAAX motif (32) . When coexpressed with GRP1(PH)-GFP, this kinase caused the translocation of GRP1(PH)-GFP to the cell periphery in the absence of insulin, confirming p110-CAAX-mediated PIP 3 generation (Fig. 4A) . Nelfinavir-treated cells showed a similar GRP1(PH)-GFP rim, suggesting that nelfinavir did not decrease PIP 3 production through increasing PIP 3 phosphatases like phosphatase and tensin homolog deleted from chromosome 10 (PTEN) or SHIP2, as previously proposed (25) . In control cells expressing p110-CAAX along with myc-GLUT4-GFP, this forced PIP 3 generation resulted in GLUT4 translocation in the absence of insulin, which was equivalent in magnitude to that observed in Fig. 1 (Fig. 4, B  and C ). Yet in cells treated with nelfinavir, this forced PIP 3 generation did not overcome the inhibitory effect on GLUT4 PM fusion. Furthermore, Akt and GSK3 phosphorylation in p110-CAAX-expressing cells were still impaired in nelfinavir-treated cells (Fig. 5) , confirming that Akt activation remained the lim-
FIG. 2.
Insulin-stimulated phosphorylation of PKB/Akt and its downstream substrates is impaired by nelfinavir (Nelf). 3T3-L1 adipocytes were treated without or with 30 M nelfinavir for 18 h and then washed and stimulated for 10 min with insulin. Cell lysates and Western blot analysis were performed as described in Materials and Methods, and membranes were blotted with antibody against PAS (A); anti-pSer473-Akt/PKB antibody and anti-pSer9-GSK3 antibody or antibodies against total Akt/PKB and GSK3 (B); or anti-PAS and anti-AS160 antibodies (C). Shown are blots representative of three to five independent experiments. Anti-PAS blots in A are shown after both long and short exposure to depict various phosphorylated PAS below signal saturation conditions. Cont, Control; pS, pSer 9.
iting step in signal propagation to GLUT4, even under forced PIP 3 generation. Collectively, these data strongly suggest that nelfinavir does not induce impairment in insulin-stimulated PIP 3 generation and that the signaling defect is attributed to a signaling step(s) downstream of PIP 3 generation, such as the activation of Akt/PKB.
Active PKB/Akt rescues the nelfinavir-induced inhibition of GLUT4 translocation
Previously, subcellular fractionation revealed that impaired insulin-stimulated translocation of PKB/Akt to the PM accompanied the nelfinavir-induced defect in GLUT4 translocation (25) . To examine the hypothesis that this failure of PKB/Akt to arrive and become phosphorylated at the PM in response to insulin was responsible for the impairment in GLUT4 translocation, we used a membrane targeted active PKB/Akt by virtue of a myristoylation sequence (myr-Akt). We first assessed whether this PM-targeted Akt would be phosphorylated in nelfinavirtreated cells, reflecting on the activity of PKB/Akt kinases (PDK1 and mammalian target of rapamycin (mTOR)-signaling complex 2 (TORC2)). As shown in Fig. 6A , nelfinavir did not attenuate PKB/Akt phosphorylation of myr-Akt on either Ser473 or Thr308. This suggests that the PI 3-kinase to PKB/Akt signal transmission defect induced by nelfinavir is not due to impaired activity of upstream PKB/Akt kinases. When coexpressed with myc-GLUT4-GFP, myr-Akt expression resulted in GLUT4 PM fusion in the absence of insulin to an extent equivalent in nonmyr-Akt expressing cells stimulated by insulin (Fig. 6, B and C, compared with Fig. 1 ). In contrast to the effect observed with p110-CAAX, the ability of myr-Akt to induce GLUT4 translocation was preserved in nelfinavir-treated cells. This finding suggests that a PKB/Akt that is active irrespective of PIP 3 generation can circumvent the insulin signaling defect induced by nelfinavir. 
Discussion
Impaired activation of PKB/Akt as a functional break point in insulin signal propagation
Defective proximal insulin signaling steps, such as decreased insulin receptor activation and reduced tyrosine phosphorylation of IRS molecules, are frequently proposed as cellular mechanisms for insulin resistance, both in vivo and in cell models. However, in some cases decreases in early signaling events are not rate limiting for signal propagation, suggesting that the func -FIG. 6 . Membrane-targeted PKB/Akt induces GLUT4 externalization in both control and nelfinavir-treated 3T3-L1 adipocytes. 3T3-L1 adipocytes were electroporated in the presence of plasmids encoding a membrane-targeted PKB/ Akt (myr Akt) and Myc-GLUT4-GFP. Cells were then treated or not with 30 M nelfinavir (Nelf) for 18 h. A, After rinsing the cells, they were stimulated for 10 min with 100 nM insulin, after which cells were fixed, permeabilized, and stained with anti-pS473-PKB/Akt or anti-pT308-PKB/Akt. B, Cells were left unstimulated with insulin, fixed, and stained for surface myc. C and D, Rims of myc staining or the myc to GFP fluorescence intensity ratio, respectively, were rated as described in Materials and Methods, and results of 20 -30 cells in each of eight independent experiments are shown.
FIG. 5.
Insulin-stimulated phosphorylation of Akt and of GSK3 are decreased in nelfinavir-treated-, p110-CAAX-, and myc-GLUT4-GFP-expressing adipocytes. 3T3-L1 adipocytes expressing a membrane-targeted catalytic subunit of PI 3-kinase (p110-CAAX) and myc-GLUT4-GFP were generated and treated or not with nelfinavir (Nelf) as in the legend for Fig. 4 . After immunostaining surface myc in nonpermeabilized cells, cells were permeabilized and incubated with antipSer473-PKB/Akt (A) or pSer9-GSK3 (B), followed by an alexa 633-conjugated secondary antibody. Confocal microscopy was performed, with acquisition in three channels. These experiments were repeated three times, and quantification of the intensity of the pGSK signal in nelfinavir treated and control cells (n ϭ 30 in each experiment) is shown in C in arbitrary units. *, P Ͻ 0.05.
tional signaling defect(s) is further downstream (20, 41) . In other situations, including in response to nelfinavir, early signaling steps including the activation of PI 3-kinase are intact (or even exaggerated), but signaling steps from PKB/Akt and downstream are impaired (5, 6, 13, 27) . Applying the same logic as for early signaling events, defective insulin-induced PKB/Akt activation still does not prove that this step is indeed the cause of insulin resistance. This is particularly true in muscle cells, in which only a marked decrease in PKB/Akt activation achieved by expression of mutated PKB/Akt translated into impaired downstream events (GLUT4 translocation) (21) . In these cells in response to a hydrogen peroxide-generating system, decrease in the activation (GTP loading) of Rac1 displayed a closer dose-response relationship to the attenuation of GLUT4 translocation than the decrease in PKB/Akt phosphorylation (22) . This suggests the possibility that parallel signaling steps to PKB/Akt activation, which are also downstream of PI 3-kinase, may constitute the actual rate-limiting step for signal propagation. On the other hand, the present study suggests that in 3T3-L1 adipocytes treated with nelfinavir, PKB/Akt is indeed a functional break point in insulin signal transduction toward GLUT4 translocation: signaling steps downstream of the activation of this key kinase, including phosphorylation of GSK3, AS160, and other PKB/Akt substrates were all decreased (Fig. 2) , even in cells with forced generation of PIP 3 by a constitutively active PI 3-kinase (Fig. 5) . Moreover, a membrane-targeted active PKB/Akt was able to promote GLUT4 translocation in nelfinavir-treated adipocytes as in control cells (Fig. 6 ). These findings strongly support the notion that PKB/Akt activity in situ is rate limiting for insulin signal propagation in response to nelfinavir.
Impaired PIP 3 sensing by PKB/Akt as a putative mechanism for insulin resistance
Even when a causative role is assigned for impaired activation of PKB/Akt in insulin resistance, multiple mechanisms may underlie this phenomenon. For example, PKB/Akt may lack the signals that are required for its activation, such as PIP 3 generation or the localization and activation of its upstream kinases (PDK1 and PDK2). In response to nelfinavir, both steps seem functionally unaffected because PIP 3 -mediated translocation of GRP1(PH)-GFP to the plasma membrane seems intact (Fig. 3) , and when PKB/Akt was targeted to the plasma membrane, it was phosphorylated normally on both Ser473 and Thr308 sites, suggesting intact PKB/Akt kinases activity (Fig. 6 ). Downstream to its activation, steady-state levels of PKB/Akt phosphorylation may still be decreased if a PKB/Akt phosphatase (like PP2A) would be activated. Yet previous studies ruled out this mechanism in response to nelfinavir (25) . Hence, one is left with the option that after nelfinavir treatment, despite apparently normal PIP 3 generation in response to insulin, PKB/Akt remains unresponsive to this event, thereby failing to translocate to the plasma membrane and to become phosphorylated and activated by PKB/Akt kinases. Thus, with the ever-increasing appreciation of the complexity of the insulin signaling cascades, it appears that multiple functional defects may contribute to the overall phenomenon of insulin resistance. This may underscore one reason for the difficulty in finding effective therapies to overcome insulin resistance. In the case of insulin resistance of adipocytes in response to nelfinavir, the mechanism appears to be the failure of PKB/Akt to sense insulininduced PIP 3 generation.
Why does PKB/Akt become insensitive to PIP 3 generated in the cell? One potential mechanism was suggested in muscle cells exposed to ceramide, implicating hyperactivated PKC in the phosphorylation of PKB directly on its Thr34 within its PH domain (the protein domain responsible for PIP 3 sensing) (17, 18) .
We were unable to demonstrate that this mechanism is operational to any appreciable degree in 3T3-L1 adipocytes: Although PKC could be coimmunoprecipitated with PKB/Akt, this association was not regulated by insulin, and nelfinavir did not seem to increase the phosphorylation of PKC (data not shown). An alternative molecular mechanism is complex formation between PKB/Akt and TRB3. This protein has been recently shown as a physiologically relevant off switch for insulin action through the inhibition of PKB/Akt in liver (19) [although this view was challenged by other observations (42, 43) ]. The probability that this mechanism underlies the effect of nelfinavir was supported by several lines of reasoning. First, nelfinavir-induced insulin resistance in adipocytes is accompanied by accelerated basal lipolysis rate (27) , and increased TRB3 expression was recently proposed also as a mechanism for increase in lipolysis (44) . Second, in cancer cells nelfinavir was suggested to induce endoplasmic reticulum stress (45) , which is an inducer of TRB3 (46) . Third, nelfinavir treatment during adipogenesis was shown to inhibit adipocyte differentiation (47) , as does overexpression of TRB3 (48) . However, although nelfinavir increased endogenous TRB3 protein content in 3T3-L1 adipocytes (supplementary Fig. 1 , published as supplemental data on The Endocrine Society's Journals Online web site at http://endo.endojournals.org), inhibiting this effect of nelfinavir by cycloheximide (data not shown) or using small interfering RNA (supplementary Fig. 1 ) did not prevent the decrease in PKB/Akt phosphorylation. Finally, oxidative/nitrative posttranslational modifications of PKB/Akt may impair its insulin-stimulated activation (49, 50) . Intriguingly, nelfinavir was proposed to induce increased radical generation and oxidative stress (24, 51) , and we found that an superoxide dismutase, superoxide dismutase/catalase-mimetic agent [Mn (III) tetrakis (4-benzoic acid) poryphrin chlorid (MnTBAP)] can protect cells from nelfinavir-induced impairment in PKB/Akt activation (24) and defective GLUT4 translocation (data not shown). Future studies should reveal whether and which oxidative/ nitrative modifications of PKB/Akt are caused by nelfinavir. Furthermore, whether oxidative/nitrative stress(es) can induce insulin resistance despite normal PIP 3 generation remains to be demonstrated.
In summary, we describe a postreceptor mechanism for adipocyte insulin resistance in response to nelfinavir, a drug associated with lipodystrophy and systemic insulin resistance. The underling mechanism involves oxidation-induced insensitivity of PKB/Akt to PIP 3 generated in response to insulin.
